Bulls vs Bears
Click to unlock major analysts' bullish and bearish positions by joining Benzinga Edge.
$70.34
1.371.99%
al cierre: Nov 21, 4:00 PM EST
$70.00
-0.34-0.48%
After hour: 6:29 PM EST
Comments
Loading...
Calificaciones de analistas, precios objetivo, pronóstico
Halozyme Therapeutics Inc tiene un precio objetivo de consenso de $69.29 basado en las calificaciones de 17 analistas. El máximo es $92, emitido por Citizens el noviembre 4, 2025. El mínimo es $42, emitido por SVB Leerink el marzo 16, 2023. Las 3 calificaciones de analistas más recientes fueron publicadas por Goldman Sachs, Citizens y JP Morgan el noviembre 18, 2025, noviembre 4, 2025 y octubre 27, 2025, respectivamente. Con un precio objetivo promedio de $71 entre Goldman Sachs, Citizens y JP Morgan, hay una 1.43% upside implícita para Halozyme Therapeutics Inc según estas calificaciones más recientes de analistas.
Firmas de analistas que realizan recomendaciones1
Goldman Sachs
Citizens
JP Morgan
Morgan Stanley
HC Wainwright & Co.
1calculado a partir de las calificaciones de los analistas
Calificaciones de analistas para Halozyme Therapeutics
Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
11/18/2025 | -20% | Goldman Sachs | $54 → $56 | Maintains | Neutral | |||
11/04/2025 | 31.43% | Citizens | $91 → $92 | Maintains | Market Outperform | |||
10/27/2025 | -7.14% | JP Morgan | $63 → $65 | Maintains | Neutral | |||
10/20/2025 | 12.86% | Morgan Stanley | $80 → $79 | Maintains | Overweight | |||
10/15/2025 | 28.57% | HC Wainwright & Co. | $90 → $90 | Reiterates | Buy → Buy | |||
10/14/2025 | — | Leerink Partners | → $70 | Upgrade | Underperform → Market Perform | |||
10/02/2025 | 28.57% | HC Wainwright & Co. | $85 → $90 | Maintains | Buy | |||
09/24/2025 | 28.57% | Benchmark | $75 → $90 | Maintains | Buy | |||
09/22/2025 | 21.43% | HC Wainwright & Co. | $75 → $85 | Maintains | Buy | |||
08/18/2025 | 14.29% | Morgan Stanley | $75 → $80 | Maintains | Overweight | |||
08/07/2025 | -10% | JP Morgan | $60 → $63 | Maintains | Neutral | |||
08/06/2025 | 30% | JMP Securities | $78 → $91 | Maintains | Market Outperform | |||
08/06/2025 | 7.14% | HC Wainwright & Co. | $72 → $75 | Maintains | Buy | |||
08/06/2025 | 7.14% | Morgan Stanley | $62 → $75 | Upgrade | Equal-Weight → Overweight | |||
07/16/2025 | -14.29% | JP Morgan | $58 → $60 | Maintains | Neutral | |||
05/29/2025 | 2.86% | HC Wainwright & Co. | $72 → $72 | Reiterates | Buy → Buy | |||
05/14/2025 | -11.43% | Morgan Stanley | $73 → $62 | Downgrade | Overweight → Equal-Weight | |||
05/13/2025 | -32.86% | Leerink Partners | — | → $47 | Downgrade | Market Perform → Underperform | ||
05/07/2025 | 4.29% | Morgan Stanley | $67 → $73 | Maintains | Overweight | |||
05/07/2025 | -7.14% | Wells Fargo | $60 → $65 | Maintains | Equal-Weight | |||
04/25/2025 | 2.86% | HC Wainwright & Co. | $72 → $72 | Reiterates | Buy → Buy | |||
04/21/2025 | -17.14% | JP Morgan | $55 → $58 | Maintains | Neutral | |||
03/06/2025 | — | HC Wainwright & Co. | — | Reiterates | Buy → Buy | |||
02/20/2025 | 7.14% | Benchmark | $75 → $75 | Reiterates | Buy → Buy | |||
02/19/2025 | 2.86% | HC Wainwright & Co. | $70 → $72 | Maintains | Buy | |||
02/14/2025 | -4.29% | Morgan Stanley | → $67 | Assumes | → Overweight | |||
02/04/2025 | — | HC Wainwright & Co. | $70 → $70 | Reiterates | Buy → Buy | |||
01/13/2025 | -18.57% | Wells Fargo | $62 → $57 | Maintains | Equal-Weight | |||
01/10/2025 | -24.29% | Piper Sandler | $52 → $53 | Maintains | Neutral | |||
01/10/2025 | — | HC Wainwright & Co. | $68 → $70 | Maintains | Buy | |||
12/30/2024 | -2.86% | HC Wainwright & Co. | $68 → $68 | Reiterates | Buy → Buy | |||
12/18/2024 | -2.86% | HC Wainwright & Co. | $68 → $68 | Reiterates | Buy → Buy | |||
11/25/2024 | -2.86% | HC Wainwright & Co. | $68 → $68 | Reiterates | Buy → Buy | |||
11/20/2024 | -2.86% | HC Wainwright & Co. | $68 → $68 | Reiterates | Buy → Buy | |||
11/04/2024 | -25.71% | Piper Sandler | $51 → $52 | Maintains | Neutral | |||
11/01/2024 | 4.29% | JMP Securities | $72 → $73 | Maintains | Market Outperform | |||
11/01/2024 | -2.86% | HC Wainwright & Co. | $65 → $68 | Maintains | Buy | |||
10/25/2024 | -7.14% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
10/07/2024 | -11.43% | Wells Fargo | $58 → $62 | Downgrade | Overweight → Equal-Weight | |||
10/04/2024 | -7.14% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
09/19/2024 | -18.57% | JP Morgan | $52 → $57 | Downgrade | Overweight → Neutral | |||
09/16/2024 | 7.14% | Benchmark | $60 → $75 | Maintains | Buy | |||
09/16/2024 | -7.14% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
09/13/2024 | -7.14% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
08/08/2024 | -14.29% | Benchmark | $60 → $60 | Reiterates | Buy → Buy | |||
08/08/2024 | -7.14% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
08/07/2024 | -7.14% | TD Cowen | $59 → $65 | Maintains | Buy | |||
08/07/2024 | -8.57% | Morgan Stanley | $59 → $64 | Maintains | Overweight | |||
08/06/2024 | -25.71% | JP Morgan | $53 → $52 | Maintains | Overweight | |||
08/01/2024 | -7.14% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
07/22/2024 | -30% | Goldman Sachs | $44 → $49 | Maintains | Neutral | |||
07/16/2024 | -7.14% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
06/26/2024 | -7.14% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
06/25/2024 | -14.29% | Benchmark | $50 → $60 | Maintains | Buy | |||
06/24/2024 | -7.14% | HC Wainwright & Co. | $65 → $65 | Reiterates | Buy → Buy | |||
06/07/2024 | -27.14% | Piper Sandler | $48 → $51 | Downgrade | Overweight → Neutral | |||
06/07/2024 | -17.14% | Wells Fargo | $48 → $58 | Maintains | Overweight | |||
06/07/2024 | -7.14% | HC Wainwright & Co. | $50 → $65 | Maintains | Buy | |||
06/04/2024 | -28.57% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
05/22/2024 | -28.57% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
05/08/2024 | 1.43% | JMP Securities | $72 → $71 | Maintains | Market Outperform | |||
05/08/2024 | -28.57% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy | |||
05/07/2024 | -28.57% | HC Wainwright & Co. | → $50 | Reiterates | Buy → Buy | |||
04/30/2024 | -28.57% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
04/17/2024 | -28.57% | HC Wainwright & Co. | $50 → $50 | Reiterates | Buy → Buy | |||
04/16/2024 | -28.57% | Benchmark | $50 → $50 | Reiterates | Buy → Buy | |||
02/29/2024 | -22.86% | TD Cowen | → $54 | Initiates | → Outperform | |||
02/21/2024 | 2.86% | JMP Securities | $72 → $72 | Reiterates | Market Outperform → Market Outperform | |||
02/21/2024 | -28.57% | HC Wainwright & Co. | $48 → $50 | Maintains | Buy | |||
01/19/2024 | -31.43% | HC Wainwright & Co. | $48 → $48 | Reiterates | Buy → Buy | |||
01/19/2024 | -28.57% | Benchmark | $50 → $50 | Reiterates | Buy → Buy | |||
01/18/2024 | 2.86% | JMP Securities | $72 → $72 | Reiterates | Market Outperform → Market Outperform | |||
01/18/2024 | -42.86% | Goldman Sachs | $45 → $40 | Maintains | Neutral | |||
01/18/2024 | -31.43% | HC Wainwright & Co. | $61 → $48 | Maintains | Buy | |||
12/26/2023 | -15.71% | Morgan Stanley | $61 → $59 | Maintains | Overweight | |||
10/20/2023 | -28.57% | Benchmark | → $50 | Reiterates | Buy → Buy | |||
10/19/2023 | -12.86% | HC Wainwright & Co. | $60 → $61 | Maintains | Buy | |||
10/09/2023 | -14.29% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy | |||
09/08/2023 | -14.29% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy | |||
08/30/2023 | -14.29% | HC Wainwright & Co. | → $60 | Reiterates | Buy → Buy | |||
08/15/2023 | -14.29% | HC Wainwright & Co. | $61 → $60 | Maintains | Buy | |||
08/10/2023 | -12.86% | Morgan Stanley | $60 → $61 | Maintains | Overweight | |||
07/24/2023 | -12.86% | HC Wainwright & Co. | → $61 | Initiates | → Buy | |||
07/24/2023 | -35.71% | Goldman Sachs | $43 → $45 | Downgrade | Buy → Neutral | |||
05/10/2023 | -5.71% | JMP Securities | → $66 | Reiterates | → Market Outperform | |||
05/10/2023 | -14.29% | Morgan Stanley | $64 → $60 | Maintains | Overweight | |||
05/10/2023 | -34.29% | Piper Sandler | → $46 | Upgrade | Neutral → Overweight | |||
03/27/2023 | -17.14% | Berenberg | → $58 | Reinstates | → Buy | |||
03/17/2023 | -31.43% | Wells Fargo | $55 → $48 | Maintains | Overweight | |||
03/16/2023 | -40% | SVB Leerink | → $42 | Downgrade | Outperform → Market Perform | |||
03/16/2023 | -21.43% | Wells Fargo | $65 → $55 | Maintains | Overweight | |||
03/06/2023 | -8.57% | Morgan Stanley | $65 → $64 | Maintains | Overweight | |||
02/23/2023 | -25.71% | JP Morgan | $54 → $52 | Maintains | Overweight | |||
02/22/2023 | -5.71% | JMP Securities | $62 → $66 | Reiterates | → Market Outperform | |||
01/11/2023 | -12.86% | SVB Leerink | $62 → $61 | Maintains | Outperform | |||
12/21/2022 | -7.14% | Morgan Stanley | $53 → $65 | Maintains | Overweight | |||
12/08/2022 | -2.86% | Benchmark | $55 → $68 | Maintains | Buy | |||
11/28/2022 | -7.14% | Wells Fargo | → $65 | Initiates | → Overweight | |||
11/22/2022 | -22.86% | JP Morgan | $53 → $54 | Maintains | Overweight |
PREGUNTAS FRECUENTES
¿Cuál es el precio objetivo de las acciones de Halozyme Therapeutics (HALO)?
El último precio objetivo de Halozyme Therapeutics (NASDAQ:HALO) fue comunicado por Goldman Sachs el noviembre 18, 2025. La firma de analistas fijó un precio objetivo para $56.00 que espera HALO a fall dentro de 12 meses (un posible -20.00% downside). 33 firmas de analistas han reportado calificaciones en el último año.
¿Cuál es la calificación más reciente de los analistas sobre Halozyme Therapeutics (HALO)?
La última calificación de analistas para Halozyme Therapeutics (NASDAQ:HALO) fue proporcionada por Goldman Sachs, y Halozyme Therapeutics mantuvo su neutral calificación.
¿Cuándo se produjo la última revisión al alza de Halozyme Therapeutics (HALO)?
La última revisión al alza de Halozyme Therapeutics Inc se produjo en octubre 14, 2025, cuando Leerink Partners elevó su precio objetivo a $70. Leerink Partners anteriormente tenía an underperform para Halozyme Therapeutics Inc.
¿Cuándo fue la última revisión a la baja de Halozyme Therapeutics (HALO)?
La última revisión a la baja de Halozyme Therapeutics Inc se produjo en mayo 14, 2025, cuando Morgan Stanley cambió su precio objetivo de $73 a $62 para Halozyme Therapeutics Inc.
¿Cuándo se publicará o actualizará la próxima calificación de los analistas para Halozyme Therapeutics (HALO)?
Los analistas llegan a las calificaciones de acciones después de hacer una investigación exhaustiva, que incluye revisar los estados financieros públicos, hablar con ejecutivos y clientes de Halozyme Therapeutics, y escuchar las teleconferencias de ganancias. La mayoría de los analistas hacen esto cada tres meses, por lo que deberías recibir 4 calificaciones por empresa al año. La última calificación de Halozyme Therapeutics se registró el noviembre 18, 2025, por lo que la próxima calificación estará disponible en torno al noviembre 18, 2026.
¿Es correcta la calificación de los analistas sobre Halozyme Therapeutics (HALO)?
Aunque las calificaciones son subjetivas y pueden cambiar, la última calificación de Halozyme Therapeutics (HALO) fue un mantuvo con un precio objetivo de $54.00 a $56.00. El precio actual al que cotiza Halozyme Therapeutics (HALO) es de $70.00, que es out of del rango previsto por el analista.
Explora calificaciones de analistas y precios objetivo sobre todos los valores.